Ovid Therapeutics Revenue and Competitors

Location

$134.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Ovid Therapeutics's estimated annual revenue is currently $214.1M per year.(i)
  • Ovid Therapeutics's estimated revenue per employee is $4,654,130
  • Ovid Therapeutics's total funding is $134.1M.
  • Ovid Therapeutics's current valuation is $213.1M. (January 2022)

Employee Data

  • Ovid Therapeutics has 46 Employees.(i)
  • Ovid Therapeutics grew their employee count by 15% last year.

Ovid Therapeutics's People

NameTitleEmail/Phone
1
Chief Human Resources OfficerReveal Email/Phone
2
Chief Corporate Affairs OfficerReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
CEOReveal Email/Phone
5
SVP Accounting and FinanceReveal Email/Phone
6
VP Safety and QualityReveal Email/Phone
7
SVP, Global Regulatory Affairs, Pharmacovigilance and BiometricsReveal Email/Phone
8
VP, Global Market Access & Patient ServicesReveal Email/Phone
9
SVP Global Regulatory Affairs, CMC, and QAReveal Email/Phone
10
VP, Preclinical ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Ovid Therapeutics?

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients. Review our community guidelines: http://www.ovidrx.com/community-guidelines/

keywords:N/A

$134.1M

Total Funding

46

Number of Employees

$214.1M

Revenue (est)

15%

Employee Growth %

$213.1M

Valuation

N/A

Accelerator

Ovid Therapeutics News

2022-04-17 - Ovid Therapeutics Inc. (NASDAQ:OVID) Expected to ...

Ovid Therapeutics reported earnings per share of $2.53 in the same quarter last year, which would indicate a negative year over year growth rate...

2022-04-06 - Ovid Therapeutics to Present at the 21st Annual Needham ...

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ... in the epilepsy therapeutic market, which is available to Needham...

2022-03-22 - $1.17 EPS Expected for Ovid Therapeutics Inc. (NASDAQ:OVID) This Quarter

Ovid Therapeutics, Inc is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare...

2019-06-05 - New BIO chair hopes for greater policy focus on rare diseases

In an interview at the BIO conference in Philadelphia Wednesday, Levin said rare diseases will be a particular area of interest for him at the organization. Ovid is also focused on development of rare neurological diseases, and its most advanced drug candidate is OV101, for Angelman syndrome – a ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.2M4615%N/A
#2
$8.4M46-39%N/A
#3
$8.9M46-30%N/A
#4
$35M4635%N/A
#5
$8.4M46-34%N/A